Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

NCT03772028 · tracked via the Priya Life Science Ireland tracker

Sponsor

The Netherlands Cancer Institute

Phase

Phase 3

Started

2020-01-01

Last updated

2026-04-08

Condition(s) studied

Ovarian Cancer

Investigational drug(s) / intervention(s)

cisplatin

cisplatin: HIPEC with cisplatin after cytoreductive surgery

Study summary

stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * candidate for primary CRS * histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer Exclusion Criteria: * history of previous malignancies within 5 years prior to inclusion * FIGO stage IV disease * complete primary cytoreduction is impossible * prior treatment for the current malignancy

Primary outcome measure(s)

overall survival — 1 year after last patient last visit

Trial sites (28)

Facility	City	Region
City of Hope	Duarte	California
MSKCC New York	New York	New York
Rigshospitalet Copenhagen	Copenhagen	Denmark
CHU de Besancon	Besançon	France
Institut Bergonié	Bordeaux	France
o Institut Bergonié, Bordeaux	Bordeaux	France
CHU Lille	Lille	France
Centre Leon Berard, Lyon	Lyon	France
CHU Lyon	Lyon	France
Institut du Cancer Montpellier	Montpellier	France
Institut de Cancerologie de l'Ouest, ICO Nantes)	Nantes	France
Institut Curie Paris	Paris	France
CHRU Strasbourg	Strasbourg	France
Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse)	Toulouse	France
Mater Misericordiae University Hospital, Dublin	Dublin	Ireland
Policlinico Sant'Orsola, Bologna	Bologna	Italy
Fondazione Policlinico A Gemelli IRCCS	Roma	Italy
Antoni van leeuwenhoek	Amsterdam	North Holland
Amsterdam UMC	Amsterdam	Netherlands
Catharina Hospital	Eindhoven	Netherlands
Medisch Spectrum Twente	Enschede	Netherlands
UMCG	Groningen	Netherlands
Leiden University Medical Center (LUMC)	Leiden	Netherlands
Maastricht UMC+	Maastricht	Netherlands
Radboud MC	Nijmegen	Netherlands
Erasmus MC	Rotterdam	Netherlands
UMCU	Utrecht	Netherlands
Alice Bjoernlund-Larsen	Uppsala	Sweden

Other trials for the same condition

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Active, not recruiting

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) Recruiting

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03772028 on ClinicalTrials.gov ↗ ← All trials in Ireland